AbbVie | ABBV - Pre Tax Profit



AbbVie reported $1.66B in Pre-Tax Profit for its fiscal quarter ending in March of 2025.


Pre Tax Profit Change Date
AbbVie USD 1.66B 3.15B Mar/2025
Abbott USD 2.15B 372M Jun/2025
ALKERMES USD 104.84M 79.35M Jun/2025
Amgen USD 1.57B 405M Jun/2025
AstraZeneca USD 3.13B 275M Jun/2025
Biogen USD 744M 432.8M Jun/2025
BioMarin Pharmaceutical USD 297.87M 59.78M Jun/2025
Bristol-Myers Squibb USD 1.77B 1.2B Jun/2025
Eisai JPY 22.4B 22.43B Jun/2025
Eli Lilly USD 6.78B 3.32B Jun/2025
Gilead Sciences USD 2.43B 780M Jun/2025
GlaxoSmithKline GBP 1.89B 221M Jun/2025
J&J USD 13.63B 8.21B Mar/2025
Medtronic USD 1.87B 612M Jul/2025
Merck USD 6.77B 864M Jun/2025
Neurocrine Biosciences USD 159.5M 144.8M Jun/2025
Novartis USD 4.53B 124M Jun/2025
Pacira USD -1927000 10.63M Jun/2025
Perrigo USD 3.2M 5.1M Jun/2025
Pfizer USD 3.04B 259M Jun/2025
Regeneron Pharmaceuticals USD 1.52B 613.7M Jun/2025
Roche Holding CHF 1.78B 2.33B Dec/2024
Sanofi EUR 1.42B 734M Jun/2025
UCB EUR 1.22B 781M Dec/2024
Ultragenyx Pharmaceutical USD -114004000 35.77M Jun/2025
United Therapeutics USD 408.4M 15.1M Jun/2025
Vertex Pharmaceuticals USD 1.28B 552.6M Jun/2025
Zoetis USD 902M 92M Jun/2025